Please ensure Javascript is enabled for purposes of website accessibility

Why BeyondSpring Stock Skyrocketed Today

By Joe Tenebruso – Aug 4, 2021 at 4:39PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biotech's experimental cancer therapy could be a game-changer.

What happened 

Shares of BeyondSpring (BYSI 0.02%) soared on Wednesday after the pharmaceutical company released promising clinical trial results for its investigational lung cancer treatment. By the close of trading, BeyondSpring's stock price was up 176% after rising as much as 211% earlier in the day. 

So what

A phase 3 trial of BeyondSpring's plinabulin treatment in combination with chemotherapy medication docetaxel to treat second and third line non-small cell lung cancer (NSCLC) reached its primary endpoint of statistically significant improvement in overall survival versus docetaxel alone.

The combination treatment study also met its secondary endpoints, including significantly improving overall response rate (the proportion of patients whose tumor is reduced by a drug), progression-free survival rate, and 24- and 36-month overall survival rates. Better still, it demonstrated a significant reduction in the incidence of grade 4 neutropenia, a condition in which an abnormally low number of white blood cells leads to an increased risk of infection.

An upwardly sloping black and white stock chart.

Investors drove BeyondSpring's share price sharply higher on Wednesday. Image source: Getty Images.

CEO Dr. Lan Huang said in a press release that the results "further validate our conviction that plinabulin, as an immune anti-cancer agent, has the potential to be a cornerstone therapy for many solid tumors."

Now what

BeyondSpring hopes to obtain approval for plinabulin in combination with docetaxel in NSCLC from the U.S. Food and Drug Administration (FDA) and China's National Medical Products Administration (NMPA). The company expects to submit its new drug application (NDA) in the first half of 2022.

Joe Tenebruso has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

BeyondSpring, Inc. Stock Quote
BeyondSpring, Inc.
BYSI
$0.60 (0.02%) $0.00

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
351%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.